Table 1.

Anti-PD-1 monotherapy approvals with PD-L1 companion diagnostic.

Clinical trials for which only PD-L1+ patients were treated	Keytruda in 1L NSCLC	KEYNOTE-024
	Tecentriq in 1L NSCLC	IMpower110
Clinical trials for which relatively few PD-L1− patients were assessed	Keytruda in chemotherapy-resistant cervical cancer  • 16% PD-L1- pts (N = 16)	KEYNOTE-158 (Cohort E)
Clinical trials demonstrating limited benefit in PD-L1− patients	Keytruda in 2L+ esophageal  • 1° endpoint met only in PD-L1 selected pts	KEYNOTE-181
	Keytruda in 1L SCCHN  • No benefit vs cetuximab in PD-L1 unselected pts	KEYNOTE-048
	Keytruda in 1L urothelial cancer  • Less benefit vs platinum-based chemo in PD-L1- pts	KEYNOTE-052 KEYNOTE-361
	Tecentriq in 1L urothelial cancer pts who are ineligible for platinum-based chemo  • Less benefit vs platinum-based chemo in PD-L1- pts	IMvigor210 IMvigor130